Transcatheter aortic valve replacement is now indicated across all risk categories of patients
with symptomatic severe aortic stenosis and has been proposed as first line option for the …

Indications for transcatheter aortic valve replacement (TAVR) have steadily increased over
the last decade since the first trials including inoperable or very high risk patients. Thus …

Background It remains controversial whether prosthesis-patient mismatch (PPM)(in general
considered moderate if indexed effective orifice area is 0.65-0.85 cm2/m2 and severe …

Transcatheter aortic valve implantation (TAVI) has become an alternative to surgical aortic
valve replacement for patients with symptomatic severe aortic stenosis in elderly and …

Aims To evaluate all-cause mortality in ViV-TAVI versus redo SAVR in patients with failed
bioprostheses. Methods Study-level meta-analysis of reconstructed time-to-event data from …

Background Limited data are available regarding clinical outcomes of valve-in-valve (ViV)
transcatheter aortic valve implantation (TAVI) following the United States Food and Drug …

Valve-in-valve (ViV) transcatheter aortic valve implantation (ViV-TAVI) in patients with failed
bioprostheses arose as an alternative to redo surgical aortic valve replacement (SAVR). To …

Background In the absence of randomized controlled trials, reports from nonrandomized
studies comparing valve‐in‐valve implantation (ViV) to redo surgical aortic valve …

Transcatheter aortic valve replacement (TAVR) has already received the green light for high‐
, intermediate‐and low‐risk profiles and is an alternative for all patients regardless of age. It …

Objective. Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) has emerged as
a useful alternative intervention to redo-surgical aortic valve replacement (Redo-SVAR) for …